With ClearTrial Portfolio Planning, available in the enterprise edition of ClearTrial version 2.7, clinical development organizations can now roll up protocol-level study plans into portfolio-level forecasts, providing instant visibility to monthly budgets, monthly resource demand, and timelines across a program, business unit, therapeutic indication, region, service provider or any other dimension, a capability to the industry. And when protocol-level assumptions change, the software automatically updates the portfolio forecast in seconds, according to ClearTrial.
Mike Soenen, managing partner of ClearTrial, said: “With version 2.7, ClearTrial continues to set the standard for clinical software that helps life sciences companies bring new, quality treatments to market rapidly. We are pleased to introduce this much-needed capability to the benefit of the industry.”